Recruiting

Study on the Safety of RP-6306 Alone or with RP-3500 or Debio 0123 for Patients with Advanced Solid Tumors

Fast replyInvestigationalNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the safety and effects of a new treatment for patients with advanced solid tumors. These are types of cancer that have spread beyond their original location and are difficult to treat. The study involves a medication called RP-6306, which is being tested alone and in combination with other drugs, RP-3500 and Debio 0123. RP-6306 is an anti-tumor agent, while RP-3500 is an ATR inhibitor, a type of drug that targets specific proteins in cancer cells. Debio 0123 is a highly selective inhibitor of the WEE1 kinase, which is another protein involved in cancer cell growth.

The purpose of the study is to assess how safe and tolerable these treatments are for patients with certain genetic changes in their tumors, such as CCNE1 amplification or mutations in genes like FBXW7. The study will also determine the best dose and schedule for these medications. Patients will take the medications orally, in the form of capsules or tablets. The study will monitor the patients' health and any side effects they experience, as well as how the cancer responds to the treatment.

Throughout the study, patients will undergo regular check-ups and tests to track their progress. The study aims to find the most effective and safe way to use these medications to help treat advanced solid tumors. The trial is expected to continue until 2027, with the goal of improving treatment options for patients with these challenging types of cancer.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Joining the study
Upon joining the study, the patient will begin by taking part in a Phase 1 trial. This trial is designed to assess the safety and tolerability of the medication RP-6306, either alone or in combination with other medications such as RP-3500 or Debio 0123.
The patient will be required to provide written informed consent before any study-specific procedures are performed.
Step 2
Medication administration
The patient will receive the medication in the form of hard capsules or tablets, which are to be taken orally.
The specific medication regimen will depend on the module of the study the patient is enrolled in. For example, RP-6306 may be administered alone or in combination with RP-3500 or Debio 0123.
Step 3
Monitoring and assessments
Throughout the study, the patient will undergo regular monitoring to assess the safety and effectiveness of the treatment. This includes laboratory assessments, vital signs, and electrocardiograms (ECGs).
The patient will also be monitored for any treatment-emergent adverse events (TEAEs) and dose-limiting toxicities (DLTs).
Step 4
Dose determination
The study aims to determine the maximum tolerated dose (MTD) of RP-6306, both as a monotherapy and in combination with other medications.
The recommended Phase 2 dose (RP2D) and preferred schedule will be established based on the findings from this phase.
Step 5
Evaluation of treatment effects
The study will evaluate the preliminary anti-tumor activity of the medications. This includes measuring changes in tumor size and assessing the overall response rate (ORR) and duration of response (DOR).
The patient may also undergo biomarker assessments and circulating tumor DNA (ctDNA) analysis to further understand the treatment's effects.
Step 6
Completion of the study
The estimated end date for the study is April 27, 2027. The patient will continue to be monitored until the study's completion or until they are no longer able to participate.
Upon completion, the patient will receive a final assessment to evaluate their overall health and the outcomes of the treatment.

Who can join the trial?

19 criteria

Sign a written informed consent form, which is a document that explains the study and confirms your agreement to participate.
Be able to follow the study's rules and procedures.
Be able to swallow tablets and capsules whole.
Have acceptable organ function, which means your organs are working well enough, as shown by specific lab tests.
Have acceptable blood function, meaning your blood cells are at healthy levels without recent transfusions or growth factors.
If you are a woman who can have children, you must have a negative pregnancy test before starting the study.
If you are a man with a female partner who can have children, you must use birth control during the study and for 6 months after, and you must not donate sperm during this time.
Any side effects from previous treatments or surgeries must have improved to a mild level.
If you had radiation therapy before, it must have been completed at least 7 days before starting the study, and you must have recovered from any immediate side effects.
You must have a life expectancy of at least 12 weeks, as judged by the study doctor.
For certain parts of the study, you must be able to eat a high-fat meal and fast for 12 hours.
You must be at least 12 years old. If you are between 12 and 17 years old, you can join only after some adults have completed a treatment cycle.
You must have a certain level of physical activity and ability, measured by specific performance scores.
You must have advanced or resistant solid tumors. If you are under 18, you can join only if there is no standard treatment available. If you are 18 or older, you can join if standard treatments are not suitable or if you choose not to have them.
If you are under 18, you must weigh at least 40 kg (about 88 pounds).
You must have a sample of your tumor tissue available for testing, or a tumor that can be safely biopsied if no sample is available.
Your tumor must have specific genetic changes, confirmed by a certified laboratory.
Certain types of endometrial cancer are eligible, with specific genetic characteristics confirmed by tests.
Your disease must be measurable according to specific criteria used in clinical studies.

Who cannot join the trial?

10 criteria

Patients who have a different type of cancer that is not an advanced solid tumor with specific genetic changes.
Patients who are not able to safely take the study medication due to other health conditions.
Patients who are currently pregnant or breastfeeding.
Patients who are participating in another clinical trial that might interfere with this study.
Patients who have had a recent major surgery or are recovering from a major surgery.
Patients who have an active infection that requires treatment.
Patients who have a history of severe allergic reactions to similar medications.
Patients who have certain heart conditions that could be affected by the study medication.
Patients who have not recovered from side effects of previous cancer treatments.
Patients who have a history of drug or alcohol abuse that could interfere with the study.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Hospital Universitario De Navarra
Verified
Pamplona, Spain
Hospital Universitario Fundacion Jimenez Diaz
Verified
Madrid, Spain
Hospital Universitario Hm Sanchinarro
Responsive
Madrid, Spain

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot yet recruitingNot recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

RP-6306
is a medication being studied for its safety and how well it is tolerated in patients with advanced solid tumors. The trial aims to find the best dose and schedule for using RP-6306 alone. It is also being tested in combination with other medications to see if it can be more effective.
RP-3500
is another medication used in combination with RP-6306. The study is looking at how safe and tolerable this combination is for patients with specific types of advanced solid tumors. The goal is to find the best dose and schedule for this combination.
Debio 0123
is a medication being tested in combination with RP-6306. This combination is being studied for its safety and tolerability in patients with certain genetic changes in their tumors. The trial also aims to find the best dose and schedule for this combination and to see if it can help reduce tumor size in specific types of cancer.

What is already known about the treatment

RP-6306 – This medication is administered orally in the form of tablets or capsules. It is currently being studied in clinical trials for its safety, tolerability, and effectiveness in treating advanced solid tumors with specific genetic mutations. The main therapeutic indication is for tumors with CCNE1 amplification or mutations in genes like FBXW7. RP-6306 works by targeting specific molecular pathways involved in tumor growth, aiming to inhibit cancer cell proliferation. It is classified as an investigational anti-cancer agent.

Investigated diseases

Advanced Solid Tumors – Advanced solid tumors are a group of cancers that originate in solid organs or tissues, such as the breast, lung, or colon, and have progressed to a more severe stage. These tumors are characterized by their ability to grow uncontrollably and invade nearby tissues. As they advance, they may spread to other parts of the body, a process known as metastasis. The progression of these tumors can vary depending on the type of cancer and its location. They often lead to symptoms such as pain, swelling, or dysfunction of the affected organ. The genetic makeup of the tumor, such as CCNE1 amplification or mutations in genes like FBXW7, can influence its behavior and response to treatment.